[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BE2015C029I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C029I2
BE2015C029I2 BE2015C029C BE2015C029C BE2015C029I2 BE 2015C029 I2 BE2015C029 I2 BE 2015C029I2 BE 2015C029 C BE2015C029 C BE 2015C029C BE 2015C029 C BE2015C029 C BE 2015C029C BE 2015C029 I2 BE2015C029 I2 BE 2015C029I2
Authority
BE
Belgium
Prior art keywords
disclosed
synthesis
novel
ceramide
udp
Prior art date
Application number
BE2015C029C
Other languages
French (fr)
Original Assignee
Univ Michigan Regents
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23182463&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Michigan Regents, Genzyme Corp filed Critical Univ Michigan Regents
Publication of BE2015C029I2 publication Critical patent/BE2015C029I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Disclosed is a novel enantiomeric synthesis of ceramide-like inhibitors of UDP-glucose: N -acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.
BE2015C029C 2001-07-16 2015-05-12 BE2015C029I2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30581401P 2001-07-16 2001-07-16
PCT/US2002/022659 WO2003008399A1 (en) 2001-07-16 2002-07-16 Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors

Publications (1)

Publication Number Publication Date
BE2015C029I2 true BE2015C029I2 (en) 2021-07-19

Family

ID=23182463

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C029C BE2015C029I2 (en) 2001-07-16 2015-05-12

Country Status (16)

Country Link
US (11) US6855830B2 (en)
EP (3) EP2266968B1 (en)
JP (6) JP5038582B2 (en)
AT (2) ATE555102T1 (en)
BE (1) BE2015C029I2 (en)
BR (3) BRPI0211379B8 (en)
CA (1) CA2453978C (en)
CY (1) CY2015028I2 (en)
DK (3) DK2067775T3 (en)
ES (3) ES2395463T3 (en)
FR (1) FR15C0036I2 (en)
HK (2) HK1132267A1 (en)
IL (3) IL159905A0 (en)
LU (1) LU92717I2 (en)
PT (3) PT2067775E (en)
WO (1) WO2003008399A1 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890949B1 (en) * 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
DK2067775T3 (en) * 2001-07-16 2012-07-16 Genzyme Corp N-ACYLSPHINGOSINGLUCOSYLTRANSFERASE INHIBITOR
WO2003045928A1 (en) * 2001-11-26 2003-06-05 Genzyme Corporation Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
US20060217560A1 (en) * 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
JP4195411B2 (en) * 2004-04-12 2008-12-10 セイコーエプソン株式会社 Method for manufacturing organic electroluminescence device
EP1811991B1 (en) * 2004-11-10 2018-11-07 Genzyme Corporation Treatment of type 2 diabetes using inhibitors of glycosphingolipid synthesis
AU2006209197A1 (en) 2005-01-26 2006-08-03 Allergan, Inc. Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
EP4293112A3 (en) 2007-01-18 2024-03-13 Genzyme Corporation Oligosaccharides comprising an aminooxy group and conjugates thereof
EP2481407B1 (en) * 2007-03-06 2018-09-26 Allergan, Inc. Compounds for use in treating cognitive disorders
US9314466B2 (en) 2007-03-06 2016-04-19 Allergan, Inc. Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
US20140179925A1 (en) 2009-09-04 2014-06-26 Allergan, Inc. Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
US8173683B2 (en) 2007-03-06 2012-05-08 Allergan, Inc. Methods for treating cognitive disorders
EP2594564B1 (en) 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CN101888840A (en) 2007-10-05 2010-11-17 简詹姆公司 Make the method for the amide derivatives treatment polycystic kidney disease of requiring mental skill
US8168631B2 (en) 2008-02-05 2012-05-01 Allergan, Inc. 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity
JP2011529500A (en) * 2008-07-28 2011-12-08 ジェンザイム コーポレーション Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular diseases
KR101687039B1 (en) 2008-10-03 2016-12-15 젠자임 코포레이션 2-acylaminopropanol-type glucosylceramide synthase inhibitors
CA2747230C (en) 2008-12-16 2019-06-11 Genzyme Corporation Oligosaccharide-protein conjugates
PL2796457T3 (en) * 2009-11-27 2017-04-28 Genzyme Corporation Genz 112638 for treating Gaucher or Fabry disease in combination therapy
EP2560428A4 (en) 2010-04-16 2016-12-28 Kyocera Corp Wireless communication system, high-power base station, low-power base station and communication control method
KR20140037082A (en) 2011-04-22 2014-03-26 겐자임 코포레이션 Modified acid alpha glucosidase with accelerated processing
WO2013059119A1 (en) 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
AU2014237569B2 (en) * 2013-03-15 2019-03-14 Concert Pharmaceuticals Inc. Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
CN105745206B (en) 2013-09-20 2019-08-13 生物马林药物股份有限公司 For treating the Glucosylceramide synthase inhibitor of disease
WO2015059679A1 (en) * 2013-10-25 2015-04-30 Dr. Reddy's Laboratories Limited Improved process for the preparation of eliglustat
US10239832B2 (en) 2013-10-29 2019-03-26 Biomarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
JP6749923B2 (en) 2015-02-02 2020-09-02 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Glucosylceramide synthase inhibitor and treatment method using the same
CN104557851B (en) * 2015-02-10 2017-04-05 苏州明锐医药科技有限公司 The preparation method of Yi Lusita
ES2716420T3 (en) 2015-04-14 2019-06-12 Sandoz Ag Crystalline eliglustat hydrochloride
WO2017068496A1 (en) * 2015-10-20 2017-04-27 Dr. Reddy' S Laboratories Limited Improved process for the preparation of eliglustat and its salts
CN105646442A (en) * 2015-10-27 2016-06-08 北京凯莱天成医药科技有限公司 Preparation method of eliglustat
US20190142782A1 (en) 2016-04-11 2019-05-16 Spedding Research Solutions Inhibitors of glucosylceramide degradation in the treatment of diseases of the motor units
CN106349210A (en) * 2016-08-24 2017-01-25 北京阳光诺和药物研究有限公司 Method for preparing tartrate EGS
CN106967042B (en) * 2017-03-21 2020-08-14 浙江奥翔药业股份有限公司 Synthesis method of eligerlat and intermediate compound thereof
CN108822072B (en) * 2017-04-11 2021-01-12 中国医学科学院药物研究所 Method for preparing Elligusurgitol
WO2018193090A2 (en) 2017-04-21 2018-10-25 Amneal Pharmaceuticals Company Gmbh Process for preparation of eliglustat hemitartrate and intermediates thereof
ZA201803719B (en) 2017-06-05 2019-04-24 Cipla Ltd Stable solid dispersions of eliglustat hemitartrate
EP3723809A1 (en) 2017-12-15 2020-10-21 Genzyme Corporation Methods for treating gaucher disease
US12064414B2 (en) 2017-12-20 2024-08-20 Aizant Drug Research Solutions Private Limited. Stable amorphous Eliglustat premix and process for the preparation thereof
CN111217791B (en) * 2018-11-27 2024-02-02 广东东阳光药业股份有限公司 Ibrutin intermediate and preparation method thereof
EP3941917A4 (en) * 2019-03-22 2022-12-21 Piramal Pharma Limited An improved process for the preparation of eliglustat and its intermediate
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
EP4048397B1 (en) 2019-10-23 2023-08-16 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors for therapeutic applications
WO2021214771A1 (en) 2020-04-23 2021-10-28 The Israel Institute of Biological Research (IIBR) Glucosylceramide synthase inhibitors for prevention and treatment of viral diseases
JP2023523454A (en) 2020-04-28 2023-06-05 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン Pyridine inhibitors of glucosylceramide synthase and methods of treatment using them
CN116120274A (en) 2021-11-12 2023-05-16 曙方(上海)医药科技有限公司 Pharmaceutically acceptable salts of irinotecan and crystalline forms thereof
EP4201403A1 (en) 2021-12-21 2023-06-28 Som Innovation Biotech, S.L. Compounds tirapazamine and quazinone for use in the treatment of gm2 gangliosidoses

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
DE3522475A1 (en) 1985-06-22 1987-01-02 Kali Chemie Pharma Gmbh NEW AROMATIC COMPOUNDS, THEIR PRODUCTION AND USE
JPH0416856A (en) 1990-05-10 1992-01-21 Canon Inc Positively chargeable nonmagnetic toner
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
CN1128951A (en) * 1993-08-13 1996-08-14 生化学工业株式会社 Remedy for nervous diseases
AU691886B2 (en) 1994-02-02 1998-05-28 Transave, Inc. Pharmaceutically active compounds and liposomes, and methods of use thereof
WO1995034530A1 (en) * 1994-06-10 1995-12-21 Seikagaku Corporation 2-acylaminopropanol compound and medicinal composition
FR2734819B1 (en) 1995-05-31 1997-07-04 Adir NOVEL COMPOUNDS OF PIPERAZINE, PIPERIDINE AND 1,2,5,6-TETRAHYDROPYRIDINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US5916911A (en) 1995-09-20 1999-06-29 The Regents Of The University Of Michigan Amino ceramide--like compounds and therapeutic methods of use
US20030073680A1 (en) * 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) * 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6255336B1 (en) * 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (en) * 1995-12-08 2007-10-17 生化学工業株式会社 Amino alcohol derivative and method for producing the derivative
NO965193L (en) * 1995-12-08 1997-06-09 Seikagaku Kogyo Kk Seikagaku C Aminal alcohol derivative and process for its preparation
JP4140984B2 (en) 1995-12-20 2008-08-27 生化学工業株式会社 Drug with differentiation-inducing action
US5916802A (en) * 1997-02-19 1999-06-29 Fritz Berthold Device for measuring ATP
US5972928A (en) * 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (en) 1997-05-23 2008-01-23 生化学工業株式会社 Amino alcohol derivatives and pharmaceuticals containing the same
JP4176170B2 (en) 1997-06-06 2008-11-05 生化学工業株式会社 Medicine containing amino alcohol derivative and therapeutic agent for abnormal proliferative disease
US6511979B1 (en) 1998-07-27 2003-01-28 Johns Hopkins University Methods for treating conditions modulated by lactosylceramide
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
EP1358172B1 (en) 2001-01-10 2009-11-18 The Regents of The University of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) * 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) * 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
DK2067775T3 (en) 2001-07-16 2012-07-16 Genzyme Corp N-ACYLSPHINGOSINGLUCOSYLTRANSFERASE INHIBITOR
US6916802B2 (en) * 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
EP2032134B1 (en) * 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis

Also Published As

Publication number Publication date
US20030050299A1 (en) 2003-03-13
WO2003008399A1 (en) 2003-01-30
US20070203223A1 (en) 2007-08-30
BR122015016313B8 (en) 2021-05-25
IL193244A0 (en) 2009-02-11
JP2005255686A (en) 2005-09-22
US20110003987A1 (en) 2011-01-06
US20080058514A1 (en) 2008-03-06
EP2266968B1 (en) 2013-01-09
BR0211379A (en) 2004-08-17
US7763738B2 (en) 2010-07-27
EP2067775B1 (en) 2012-04-25
US20170334888A1 (en) 2017-11-23
FR15C0036I1 (en) 2015-06-26
BRPI0211379B8 (en) 2021-05-25
ATE555102T1 (en) 2012-05-15
ES2395122T3 (en) 2013-02-08
ES2395463T3 (en) 2013-02-15
CA2453978A1 (en) 2003-01-30
JP6182254B2 (en) 2017-08-16
US7265228B2 (en) 2007-09-04
DK2067775T3 (en) 2012-07-16
EP2266968A3 (en) 2011-05-18
ES2399323T3 (en) 2013-03-27
CY2015028I1 (en) 2016-07-27
US20150148534A1 (en) 2015-05-28
JP5038582B2 (en) 2012-10-03
BR122015016314B8 (en) 2021-05-25
HK1132267A1 (en) 2010-02-19
EP2067775A1 (en) 2009-06-10
US7196205B2 (en) 2007-03-27
PT2266968E (en) 2013-02-25
US20210171507A1 (en) 2021-06-10
JP4708073B2 (en) 2011-06-22
US7615573B2 (en) 2009-11-10
US8138353B2 (en) 2012-03-20
LU92717I2 (en) 2015-11-24
JP2017075151A (en) 2017-04-20
ATE554082T1 (en) 2012-05-15
CY2015028I2 (en) 2016-07-27
JP2010095546A (en) 2010-04-30
US9546161B2 (en) 2017-01-17
US6855830B2 (en) 2005-02-15
IL159905A0 (en) 2004-06-20
US20190322649A1 (en) 2019-10-24
US20050009872A1 (en) 2005-01-13
US8779163B2 (en) 2014-07-15
DK2266968T3 (en) 2013-04-08
JP2013136618A (en) 2013-07-11
PT2067775E (en) 2012-07-16
IL159905A (en) 2009-05-04
JP5227348B2 (en) 2013-07-03
JP2005502635A (en) 2005-01-27
HK1153733A1 (en) 2012-04-05
BRPI0211379B1 (en) 2018-02-14
CA2453978C (en) 2011-10-11
FR15C0036I2 (en) 2016-05-27
EP2266968A2 (en) 2010-12-29
BR122015016314B1 (en) 2019-04-16
US20050222244A1 (en) 2005-10-06
ES2395463T4 (en) 2013-02-12
US20120296088A1 (en) 2012-11-22
BR122015016313B1 (en) 2019-04-16
DK1409467T3 (en) 2012-07-16
JP2015180656A (en) 2015-10-15
PT1409467E (en) 2012-10-24
EP1409467B1 (en) 2012-04-18
EP1409467A1 (en) 2004-04-21

Similar Documents

Publication Publication Date Title
FR15C0036I1 (en)
AU2002348261A1 (en) Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors
PT923554E (en) N-BENZYLPIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES
HRP20020997A2 (en) Serine protease inhibitors
NZ329532A (en) Diazepino-indoles as phosphodiesterase iv inhibitors
PT1385518E (en) Benzimidazolone compounds
IL132690A0 (en) Prostaglandin pharmaceutical compositions
AU5239700A (en) Process for the synthesis of n-(4-cyano-3-trifluoromethylphenyl)-3-(4-fluorophenyl-sulfon l)-2-hydroxy-2-methyl-propionamide
AU2003248647A1 (en) Stereoselective synthesis of 1,2-disubstituted cycloalkyls
AP9901698A0 (en) Novel process.
PL367774A1 (en) Synthesis and intermediates
MXPA03006057A (en) Process for preparing (plusmn;) trans-4 -p-fluorophenyl -3-hydroxymethyl -1-methylpiperidine.
IL139773A0 (en) Morphine-6-glucuronide synthesis
CY1113586T1 (en) A N-ACYLOSYFINGOUS Glycosyltransferase Suspension
SI1286965T1 (en) Piperidine compounds and process for providing such
IT1313665B1 (en) New production of 7-alpha-alkyl-17-beta-hydroxy-19-norpregn-5(10)-en-20-in-3-ones
NO20030876L (en) Process for racemization of 1-benzyl-4- (4-fluorophenyl) -3-hydroxymethyl-1,2,3,6-tetrahydropyridine for use as an intermediate in the synthesis of paroxetine